Becker's Spine Review

Becker's November 2021 Spine Review

Issue link:

Contents of this Issue


Page 63 of 63

It's time to move the needle on reducing non-unions. Today, nearly 1 in 5 fusions end in failure. But we have the power to change it. MagnetOs isn't like other bone grafts. It grows bone even in soft tissue thanks to our unique NeedleGrip TM surface technology which provides traction for our body's vitally important 'pro-healing' immune cells (M2 macrophages). *†1 This in turn, unlocks previously untapped potential to stimulate stem cells - and form new bone throughout the graft. The growing body of science behind MagnetOs is called osteoimmunology. 2-4 But for surgeons and their patients it means one thing: a more efficient and predictable fusion. * So, are you ready to move the needle? Get in touch with us today at: References: 1. Duan, et al. eCM. 2019;37:60-73. 2. Van Dijk, et al. eCM. 2021;41:756-73. 3. Van Dijk, et al. JOR Spine. 2018;e1039. 4. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090. *MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion. Results from in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit † MagnetOs is not cleared by FDA as an osteoinductive bone graft. Manufactured by Kuros Biosciences BV, Prof Bronkhorstlaan 10, Building 48, 3723 MB Bilthoven, The Netherlands. MagnetOs and NeedleGrip are trademarks of Kuros Biosciences. PROMO/MAG/US/029-21/R00 Aug '21 PROMO_MAG_US_029-21_R00.indd 1 PROMO_MAG_US_029-21_R00.indd 1 01-10-2021 10:47 01-10-2021 10:47

Articles in this issue

Links on this page

view archives of Becker's Spine Review - Becker's November 2021 Spine Review